Carboplatin - Revision history

Lazy at 08:26, 18 January 2025

2025-01-18T08:26:45Z

← Older revision		Revision as of 01:26, 18 January 2025
Line 15:		Line 15:
	\|book_text=Carboplatin's role in treating recurrent glioma, including GBM, is under active exploration, with early studies and ongoing trials investigating its efficacy and safety in combination with other therapeutic agents. Its lower toxicity profile compared to other platinum-based chemotherapies, like cisplatin, makes it an attractive option for recurrent glioma treatment strategies, pending further evidence from current research efforts.		\|book_text=Carboplatin's role in treating recurrent glioma, including GBM, is under active exploration, with early studies and ongoing trials investigating its efficacy and safety in combination with other therapeutic agents. Its lower toxicity profile compared to other platinum-based chemotherapies, like cisplatin, makes it an attractive option for recurrent glioma treatment strategies, pending further evidence from current research efforts.
	\|treatment_category=Other chemotherapy agents at recurrence		\|treatment_category=Other chemotherapy agents at recurrence
	}}		\|overview=Carboplatin is an FDA-approved chemotherapy agent primarily used for various cancers, including ovarian and lung cancer, and is currently being explored for its efficacy in treating recurrent Glioblastoma Multiforme (GBM) and high-grade glioma, particularly in combination with other agents such as PARP inhibitors. Despite its lower toxicity compared to cisplatin, ongoing clinical trials are needed to determine its overall survival benefits and efficacy in these patient populations.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:42:26Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:42, 12 November 2024
Line 14:		Line 14:
	\|toxicity_explanation=Carboplatin is generally preferred over cisplatin due to its significantly lower toxicity profile, though myelosuppression remains a concern. The combination with Talazoparib is under study to determine the safety and tolerability of this novel therapeutic approach.		\|toxicity_explanation=Carboplatin is generally preferred over cisplatin due to its significantly lower toxicity profile, though myelosuppression remains a concern. The combination with Talazoparib is under study to determine the safety and tolerability of this novel therapeutic approach.
	\|book_text=Carboplatin's role in treating recurrent glioma, including GBM, is under active exploration, with early studies and ongoing trials investigating its efficacy and safety in combination with other therapeutic agents. Its lower toxicity profile compared to other platinum-based chemotherapies, like cisplatin, makes it an attractive option for recurrent glioma treatment strategies, pending further evidence from current research efforts.		\|book_text=Carboplatin's role in treating recurrent glioma, including GBM, is under active exploration, with early studies and ongoing trials investigating its efficacy and safety in combination with other therapeutic agents. Its lower toxicity profile compared to other platinum-based chemotherapies, like cisplatin, makes it an attractive option for recurrent glioma treatment strategies, pending further evidence from current research efforts.
	\|~~category~~=Other chemotherapy agents at recurrence		\|treatment_category=Other chemotherapy agents at recurrence
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Carboplatin |FDA_approval=Yes, approved for various cancers including ovarian and lung cancer; used off-label for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) and high-grade glioma |clinical_trial_phase=Exploratory and Phase 1/2 trials for recurrent glioma in combination with other agents |common_side_effects=Less toxicity compared to cisplatin, but may include myelosuppression, nausea, and potential for liver enzyme elevation |OS_with..."

2024-03-31T04:47:47Z

Created page with "{{TreatmentInfo |drug_name=Carboplatin |FDA_approval=Yes, approved for various cancers including ovarian and lung cancer; used off-label for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) and high-grade glioma |clinical_trial_phase=Exploratory and Phase 1/2 trials for recurrent glioma in combination with other agents |common_side_effects=Less toxicity compared to cisplatin, but may include myelosuppression, nausea, and potential for liver enzyme elevation |OS_with..."

New page

{{TreatmentInfo
|drug_name=Carboplatin
|FDA_approval=Yes, approved for various cancers including ovarian and lung cancer; used off-label for GBM
|used_for=Recurrent Glioblastoma Multiforme (GBM) and high-grade glioma
|clinical_trial_phase=Exploratory and Phase 1/2 trials for recurrent glioma in combination with other agents
|common_side_effects=Less toxicity compared to cisplatin, but may include myelosuppression, nausea, and potential for liver enzyme elevation
|OS_without=Not specified
|OS_with=Not directly specified; ongoing studies aim to clarify Carboplatin's impact on survival in recurrent glioma
|PFS_without=Not applicable
|PFS_with=Early studies indicate variable results; ongoing trials, including combinations with PARP inhibitors, aim to determine efficacy
|usefulness_rating=Pending further clinical trials and data
|usefulness_explanation=Carboplatin, especially in combination with agents like Talazoparib, represents a promising line of investigation for recurrent GBM and high-grade glioma. Early research suggests variable efficacy, with the potential for meaningful clinical benefit in specific patient populations.
|toxicity_level=2
|toxicity_explanation=Carboplatin is generally preferred over cisplatin due to its significantly lower toxicity profile, though myelosuppression remains a concern. The combination with Talazoparib is under study to determine the safety and tolerability of this novel therapeutic approach.
|book_text=Carboplatin's role in treating recurrent glioma, including GBM, is under active exploration, with early studies and ongoing trials investigating its efficacy and safety in combination with other therapeutic agents. Its lower toxicity profile compared to other platinum-based chemotherapies, like cisplatin, makes it an attractive option for recurrent glioma treatment strategies, pending further evidence from current research efforts.
|category=Other chemotherapy agents at recurrence
}}